Global Sulfamethoxazole Market Insights, Forecast to 2028

Sulfamethoxazole (SMZ or SMX) is an antibiotic. It is used for bacterial infections such as urinary tract infections, bronchitis, and prostatitis and is effective against both gram negative and positive bacteria such as Listeria monocytogenes and E. coli.
Market Analysis and Insights: Global Sulfamethoxazole Market
Due to the COVID-19 pandemic, the global Sulfamethoxazole market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Generic accounting for % of the Sulfamethoxazole global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Sulfamethoxazole market size is valued at US$ million in 2021, while the US and Europe Sulfamethoxazole are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Sulfamethoxazole landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Sulfamethoxazole include Roche, Ascot Pharma, Teva, Mylan, Novartis, Watson laboratories, Shionogi, AHPL and Genefar B.V., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Sulfamethoxazole Scope and Segment
Sulfamethoxazole market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Sulfamethoxazole market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Generic
Patent
Segment by Application
Hospital
Drug Store
By Company
Roche
Ascot Pharma
Teva
Mylan
Novartis
Watson laboratories
Shionogi
AHPL
Genefar B.V.
Polfa Pabianice
Amneal Pharmaceuticals
Aurobindo Pharma
Glenmark
Chartwell Pharma
Hi-Tech
Sun Pharma
Johnson and Johnson
Yung Chi
Aspen
GlaxoSmithKline
Arrow Pharmaceuticals
Sanbe
Kalbe
Laboratorio Teuto Brasileiro
EastPharma
Berlin-Chemie
Arena Pharmaceuticals
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE